Amicus Therapeutics (NASDAQ:FOLD) Price Target Raised to $19.00 at JPMorgan Chase & Co.

Amicus Therapeutics (NASDAQ:FOLD) had its price target raised by analysts at JPMorgan Chase & Co. from $18.00 to $19.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price target points to a potential upside of 113.48% from the stock’s current price.

FOLD has been the topic of a number of other reports. Needham & Company LLC upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a report on Thursday, September 18th. The Goldman Sachs Group lifted their price objective on Amicus Therapeutics from $9.00 to $11.00 and gave the company a “neutral” rating in a research note on Wednesday. Zacks Research upgraded shares of Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, October 6th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Amicus Therapeutics in a report on Wednesday, October 8th. Finally, Wall Street Zen upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating in a report on Sunday, October 26th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Amicus Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $16.38.

Amicus Therapeutics Stock Performance

Shares of NASDAQ:FOLD traded down $0.29 during midday trading on Thursday, reaching $8.90. The company’s stock had a trading volume of 6,713,084 shares, compared to its average volume of 4,189,648. The firm has a market capitalization of $2.74 billion, a PE ratio of -74.16 and a beta of 0.66. The stock has a fifty day moving average of $8.25 and a 200 day moving average of $7.06. Amicus Therapeutics has a twelve month low of $5.51 and a twelve month high of $11.36. The company has a quick ratio of 2.29, a current ratio of 3.21 and a debt-to-equity ratio of 1.92.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.17 EPS for the quarter, beating analysts’ consensus estimates of $0.12 by $0.05. The business had revenue of $169.06 million during the quarter, compared to analysts’ expectations of $165.24 million. Amicus Therapeutics had a negative return on equity of 5.07% and a negative net margin of 6.67%.The business’s revenue was up 19.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.10 earnings per share. Amicus Therapeutics has set its FY 2025 guidance at EPS. On average, equities analysts expect that Amicus Therapeutics will post 0.15 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider David Michael Clark sold 25,643 shares of the company’s stock in a transaction on Tuesday, November 4th. The stock was sold at an average price of $9.51, for a total value of $243,864.93. Following the completion of the sale, the insider owned 322,618 shares in the company, valued at $3,068,097.18. This represents a 7.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 2.20% of the company’s stock.

Hedge Funds Weigh In On Amicus Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Strs Ohio acquired a new position in shares of Amicus Therapeutics during the 1st quarter valued at about $30,000. Osaic Holdings Inc. boosted its position in Amicus Therapeutics by 450.1% during the second quarter. Osaic Holdings Inc. now owns 4,104 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 3,358 shares during the period. EverSource Wealth Advisors LLC grew its holdings in Amicus Therapeutics by 472.6% during the second quarter. EverSource Wealth Advisors LLC now owns 4,455 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 3,677 shares during the last quarter. PNC Financial Services Group Inc. raised its position in shares of Amicus Therapeutics by 211.4% in the first quarter. PNC Financial Services Group Inc. now owns 5,151 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 3,497 shares during the period. Finally, Versant Capital Management Inc lifted its stake in shares of Amicus Therapeutics by 499.1% in the third quarter. Versant Capital Management Inc now owns 5,266 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 4,387 shares during the last quarter.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.